Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland
1996

Screening for Prostate Cancer Using PSA in Finland

Sample size: 600 publication Evidence: moderate

Author Information

Author(s): A Auvinen, T Tammela, U-H Stenman, I Uusi-Erkkila, J Leinonen, FH Schröder, M Hakama

Primary Institution: Finnish Centre for Radiation and Nuclear Safety

Hypothesis

Is it feasible to screen the general population for prostate cancer using serum prostate-specific antigen (PSA) levels?

Conclusion

A population-based study in Finland is feasible, and the PSA test properties are suitable for a randomized screening study.

Supporting Evidence

  • 77% of invited men participated in the screening.
  • Six cases of prostate cancer were detected among the 230 participating men.
  • The positive predictive value of the screening test was 24%.
  • Five out of six detected cancers were clinically localized.
  • The study suggests that PSA screening is acceptable to Finnish men aged 55-65.

Takeaway

The study tested if checking blood for prostate cancer is a good idea for Finnish men, and it found that many men were willing to participate.

Methodology

A random sample of 600 men aged 55, 60, and 65 years was identified, with half invited to participate in PSA screening.

Potential Biases

The study may have selection bias due to the nature of the randomization and participation.

Limitations

The study had a small sample size and did not evaluate satisfaction or reasons for non-participation.

Participant Demographics

Men aged 55, 60, and 65 years from the Finnish Population Registry.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication